U.S. Electronic Equipment and Components Stock News

Brown-Forman just gave investors two things to notice: a 2% boost to its quarterly dividend and the U.S. debut of New Mix, Mexico’s top-selling ready-to-drink tequila cocktail. Together, these moves reflect optimism about the company’s direction. See our latest analysis for Brown-Forman. Brown-Forman’s new product debut and dividend boost come at a time when the company’s momentum has been under pressure, with a year-to-date share price return of -24.96% and a one-year total shareholder...

Alvotech recently lowered its full-year 2025 revenue guidance to US$570 million–US$600 million, revising its forecast by around 10% below the prior midpoint after earlier raising and reaffirming it earlier this year. This shift in expectations marks a meaningful change in management's outlook, coming soon after positive regulatory progress and improved profitability were reported. We'll examine how this unexpected revenue guidance cut may alter sentiment on Alvotech's investment case and...

T. Rowe Price Group (TROW) stock has experienced some downward pressure over the past month, sliding by 7%. This has caught the attention of investors who are now considering whether current valuations reflect long-term fundamentals. See our latest analysis for T. Rowe Price Group. After a steady run earlier this year, T. Rowe Price Group’s 1-year total shareholder return is down 13.5%, with the share price sliding 6.7% over the past month and 14.2% year-to-date. This recent downtick suggests...

General Dynamics recently secured a US$2.28 billion contract modification from the U.S. Navy for advance procurement and construction of Columbia-class ballistic missile submarine hulls, with project completion expected by December 2031. This substantial contract expansion bolsters General Dynamics' role as a primary U.S. defense supplier and extends its order backlog, providing increased revenue visibility for years ahead. We'll now explore how this significant Navy contract award shapes...

Regencell Bioscience Holdings recently disclosed that Pomerantz LLP is investigating potential securities law violations following a subpoena from the U.S. Department of Justice concerning the company’s trading and corporate practices. The company warned it expects significant legal expenses and potential government fines as a result of the ongoing inquiry, raising investor concerns about future impacts. We’ll explore how anticipated legal and regulatory costs could influence Regencell...

Earlier this week, Bio-Techne announced that it entered into a licensing agreement with Seattle-based Monod Bio, securing exclusive commercial rights to a subset of AI-designed NovoBody Duo molecules that expand its recombinant protein and diagnostics portfolio. This move reinforces Bio-Techne's emphasis on AI-driven protein innovation for next-generation research and diagnostics, and positions the company at the forefront of precision medicine advancements. We'll explore how Bio-Techne's...

Meritage Homes (MTH) announced a new quarterly cash dividend of $0.43 per share and highlighted significant year-to-date share repurchases. In addition, management plans $100 million in buybacks each quarter during 2026. See our latest analysis for Meritage Homes. Meritage Homes has seen its share price retreat recently, with a 1-month share price return of -8.0% and a year-to-date decline of -13.6%. Despite this, the company’s three- and five-year total shareholder returns of 60.1% and 49.6%...

EyePoint Pharmaceuticals recently announced that its independent Data Safety Monitoring Committee completed the second scheduled review of the pivotal Phase 3 DURAVYU™ trial for wet age-related macular degeneration (wet AMD), supporting continued enrollment and progression of the study. This milestone emphasizes DURAVYU’s potential to address unmet needs in wet AMD by offering a sustained-release treatment that targets multiple disease pathways, setting it apart from current therapies. We'll...

Carvana stock saw renewed momentum after several analysts reaffirmed their positive outlook on the company. The latest analyst updates follow a quarter marked by strong growth in retail unit sales and improvement in operational efficiency, including expanded same-day delivery. Investors are now watching closely to see how these factors shape Carvana’s growth trajectory over the coming months. See our latest analysis for Carvana. Carvana's share price has shown tremendous strength this year,...

Celcuity Inc. recently announced the completion of its New Drug Application submission to the U.S. FDA for gedatolisib for use in HR-positive, HER2-negative advanced breast cancer, under the FDA's Real-Time Oncology Review program. This milestone submission is supported by positive Phase 3 data and follows Breakthrough Therapy and Fast Track designations for gedatolisib, potentially streamlining its regulatory path. We'll explore how the combination of favorable clinical data and expedited...

Ever wondered if Coursera is truly worth its current price, or if the stock is hiding more value than meets the eye? You are not alone. The real story may surprise you. Coursera has seen its share price slide 6.3% over the last week and 26.4% over the past month, but it is still up 13.2% over the last year. This demonstrates that there is both opportunity and risk in the mix. Recent headlines about Coursera's growing partnerships with universities and tech firms, along with ongoing...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

T-Mobile US, Inc. ( NASDAQ:TMUS ) is about to trade ex-dividend in the next 4 days. The ex-dividend date occurs one day...

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

Mastercard (MA) shares saw relatively muted movement in recent trading sessions, reflecting a lack of major headlines or market-moving events. Investors may be reassessing the company’s performance and valuation as the broader payment sector evolves. See our latest analysis for Mastercard. Mastercard’s share price has cooled off lately, dipping nearly 8% over the past month. This comes after a subdued period for the payment sector overall. While momentum has faded in the short term, the...

Following a session where Marvell Technology's stock dropped 3.44%, investors are digesting recent analyst opinion shifts and the company's anticipated December 2 earnings report, which is projected to show significant year-on-year gains in earnings and revenue. Marvell's data center revenue nearly doubled year-over-year last quarter, driven by high demand for custom AI silicon and a strong focus on AI infrastructure design. We’ll explore how analyst debate about Marvell’s AI positioning and...

Earlier this month, National Vision Holdings reaffirmed its 2025 outlook and unveiled a multi-year transformation plan that includes expectations for high-single-digit annual revenue growth through 2030, strategic investments, and significant store expansion. An important aspect is the company's phased investment priorities, with transformation initiatives in 2026-2027 and accelerated new store openings projected for 2028-2030, pointing to a focused approach in strengthening its growth...

Citigroup (C) announced a sweeping reorganization, folding its U.S. Retail Bank into the Wealth business and integrating relationship tiers under one leader. The company also outlined a planned Chief Financial Officer transition for next year. See our latest analysis for Citigroup. Citigroup’s latest shake-up comes on the heels of an already robust year for shareholders. Even after a modest pullback this week, the stock boasts a year-to-date share price return of nearly 40 percent and a...

Credicorp (NYSE:BAP) released its third quarter earnings, highlighting increases in both net interest income and net income compared to the same period last year. The results suggest that business momentum continues as the year-end approaches. See our latest analysis for Credicorp. Credicorp’s latest results come following a strong run in the stock’s total shareholder return, which sits at 32% over the past year and more than doubles across three and five years. Even after a minor dip in...

Winmark (WINA) has seen shares trade mostly sideways this month, trailing the broader market’s momentum. Investors seem keen to revisit its underlying business, as recent performance trends prompt a closer look at its valuation and growth trajectory. See our latest analysis for Winmark. Over the past year, Winmark’s share price momentum has hit a bit of a lull, even as the company posts consistent growth in both revenue and profits. With a 1-year total shareholder return of just over 5%,...

Coca-Cola (KO) remains an industry mainstay for income-focused investors, drawing attention for its reliable performance. Recent share movement has been fairly muted. As a result, current interest centers on how its fundamentals support long-term value amid shifting market trends. See our latest analysis for Coca-Cola. Coca-Cola’s share price has steadily advanced this year, gaining 15.15% year-to-date, and its one-year total shareholder return sits at a robust 15.04%. That enduring appeal...

On November 18, 2025, U.S. Physical Therapy, Inc. (NYSE:USPH) announced that its Board of Directors authorized a share repurchase program, allowing the company to buy back up to US$25 million of its outstanding shares. This initiative may reflect management's confidence in the company's prospects and is often viewed by investors as a means to support shareholder value. We'll explore how the newly authorized US$25 million share buyback could influence U.S. Physical Therapy's investment...

Wondering if Symbotic’s recent run-up is all hype or actually backed by value? Let’s break down what’s really going on with this high-flying stock. After a jaw-dropping 121.4% year-to-date climb and a 347.8% gain over three years, Symbotic recently took a breather, dropping 21.7% over the past month. Investor excitement has been fueled by high-profile new automation contracts and growing headlines around warehouse robotics. However, short-term volatility has also increased as the broader...

Earlier this month, Ionis Pharmaceuticals and partner Otsuka Pharmaceuticals announced that the European Medicines Agency’s CHMP adopted a positive opinion for DAWNZERA (donidalorsen) in hereditary angioedema, while Ionis separately reported highly positive Phase 3 results for olezarsen in severe hypertriglyceridemia. An important insight is that these advances could open Ionis to new patient populations in both rare and broader cardiometabolic disease indications, supporting upcoming...